Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter European Research Trial with Cilazapril after Angiopla

No abstract is available for this paper.

• Publication year

  1992

• Venue

  Circulation

• Publication date

  1992-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/01.CIR.86.1.100PMID 1535568
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cardiac Imaging: A Companion to Braunwald's Heart Disease

  1992cited by this paper
• Lumen narrowing after percutaneous transluminal coronary balloon angioplasty follows a near gaussian distribution: a quantitative angiographic study in 1,445 successfully dilated lesions.

  1992cited by this paper
• Prevention of restenosis after percutaneous transluminal coronary angioplasty: the search for a "magic bullet".

  1991cited by this paper
• The metabolic syndrome and signal transduction of gene expression.

  1991cited by this paper
• Restenosis following coronary angioplasty

  1991cited by this paper
• Oral Administration of DuP 753, a Specific Angiotensin II Receptor Antagonist, to Normal Male Volunteers: Inhibition of Pressor Response to Exogenous Angiotensin I and II

  1991cited by this paper
• Prevention of Restenosis After Percutaneous Transluminal Coronary Angioplasty With Thromboxane A2‐Receptor Blockade: A Randomized, Double‐Blind, Placebo‐Controlled Trial

  1991cited by this paper
• Prevention of restenosis after percutaneous transluminal coronary angioplasty with thromboxane A2-receptor blockade. A randomized, double-blind, placebo-controlled trial. Coronary Artery Restenosis Prevention on Repeated Thromboxane-Antagonism Study (CARPORT).

  1991cited by this paper
• Role of basic fibroblast growth factor in vascular lesion formation.

  1991cited by this paper
• Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall.

  1991cited by this paper
• Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor.

  1991influential reference
• Angiotensin converting enzyme inhibition reduces restenosis in experimental angioplasty

  1991cited by this paper
• Effects of Angiotensin Converting Enzyme Inhibition With Ciiazapril on Intimal Hyperplasia in Injured Arteries and Vascular Grafts in the Baboon

  1991cited by this paper
• Cilazapril suppresses myointimal proliferation after vascular injury: effects on growth factor induction in vascular smooth muscle cells.

  1991cited by this paper
• Prevention of restenosis by lovastatin after successful coronary angioplasty.

  1991cited by this paper
• A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies.

  1991cited by this paper
• Patterns in visual interpretation of coronary arteriograms as detected by quantitative coronary arteriography.

  1991cited by this paper
• Intimal lesion formation in rat carotid arteries after endothelial denudation in absence of medial injury.

  1990cited by this paper
• PDGF ligand and receptor gene expression during repair of arterial injury

  1990cited by this paper
• Detection of restenosis after successful coronary angioplasty: improved clinical decision making with use of a logistic model combining procedural and follow-up variables.

  1990cited by this paper
• Restenosis after successful percutaneous transluminal coronary angioplasty : serial angiographic follow-up of 229 patients

  1990cited by this paper
• Induction of Thrombospondin Expression in Vascular Smooth Muscle Cells by Angiotensin II

  1990cited by this paper
• The proliferative response to vascular injury is suppressed by angiotensin-converting enzyme inhibition.

  1990cited by this paper
• Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation.

  1990cited by this paper
• Role of platelets in smooth muscle cell proliferation and migration after vascular injury in rat carotid artery.

  1989influential reference
• Induction of platelet-derived growth factor A-chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells.

  1989cited by this paper
• Correlation between plasma concentration of cilazapril and haemodynamic and hormonal effects in healthy man.

  1989cited by this paper
• Restenosis After Coronary Angioplasty: Potential Biologic Determinants and Role of Intimal Hyperplasia

  1989cited by this paper
• Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury.

  1989cited by this paper
• Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty.

  1988cited by this paper
• A major part of platelet-derived growth factor purified from human platelets is a heterodimer of one A and one B chain.

  1988cited by this paper
• Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 229 patients.

  1988cited by this paper
• Coronary angioplasty for unstable angina: immediate and late results in 200 consecutive patients with identification of risk factors for unfavorable early and late outcome.

  1988cited by this paper
• Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months.

  1988cited by this paper
• Percutaneous transluminal coronary angioplasty in 1985-1986 and 1977-1981. The National Heart, Lung, and Blood Institute Registry.

  1988cited by this paper
• Multilesion coronary angioplasty: clinical and angiographic follow-up.

  1987cited by this paper
• Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty.

  1987cited by this paper
• Platelet accumulation in experimental angioplasty: time course and relation to vascular injury.

  1987cited by this paper
• Influence of blood pressure on development of aortic medial smooth muscle hypertrophy in spontaneously hypertensive rats.

  1987cited by this paper
• The pathogenesis of atherosclerosis--an update.

  1986cited by this paper
• Replication of smooth muscle cells in vascular disease.

  1986cited by this paper
• Restenosis after successful coronary angioplasty in patients with single-vessel disease.

  1986cited by this paper
• Angiographic morphology and the pathogenesis of unstable angina pectoris.

  1985cited by this paper
• Balloon angioplasty. Natural history of the pathophysiological response to injury in a pig model.

  1985cited by this paper
• Assessment of short-, medium-, and long-term variations in arterial dimensions from computer-assisted quantitation of coronary cineangiograms.

  1985cited by this paper
• Recurrence rate after successful coronary angioplasty.

  1985cited by this paper
• Hyperplastic growth response of vascular smooth muscle cells following induction of acute hypertension in rats by aortic coarctation.

  1985cited by this paper
• True Versus Immunoreactive Angiotensin II in Human Plasma

  1985cited by this paper
• Intracoronary thrombus: role in coronary occlusion complicating percutaneous transluminal coronary angioplasty.

  1985cited by this paper
• Angiographie morphology and the pathogenesis of unstable angina pectoris

  1985cited by this paper
• Percutaneous Transluminal Coronary Angioplasty: Report of Complications from the National Heart, Lung, and Blood Institute PTCA Registry

  1983cited by this paper
• Vascular Smooth Muscle Cell Hypertrophy and Hyperploidy in the Goldblatt Hypertensive Rat

  1983influential reference
• Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty.

  1979cited by this paper

• Impact of renin-angiotensin system inhibitors after revascularization of patients with left main coronary artery disease

  2021cites this paper
• Hydrogen Sulphide Release via the Angiotensin Converting Enzyme Inhibitor Zofenopril Prevents Intimal Hyperplasia in Human Vein Segments and in a Mouse Model of Carotid Artery Stenosis.

  2021cites this paper
• The quest for effective pharmacological suppression of neointimal hyperplasia.

  2020cites this paper
• Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers (ACEI/ARB) are Associated with Improved Limb Salvage After Infrapopliteal Interventions for Critical Limb Ischemia.

  2020cites this paper
• PGE2 enhanced TNF&agr;‐mediated IL‐8 induction in monocytic cell lines and PBMC

  2019cites this paper
• Rate of Cough During Treatment With Angiotensin‐Converting Enzyme Inhibitors: A Meta‐Analysis of Randomized Placebo‐Controlled Trials

  2019cites this paper
• Atherosclerosis Induced by a High-Cholesterol and High-Fat Diet in the Inbred Strain of the Wuzhishan Miniature Pig

  2018cites this paper
• Positive Vessel Remodelling

  2018cites this paper
• Renin-angiotensin system gene polymorphisms and coronary artery disease in Saudi patients with diabetes mellitus.

  2017cites this paper
• Renin–angiotensin system gene polymorphisms among Saudi patients with coronary artery disease

  2014cites this paper
• Long-term effects of ACE inhibitor on vascular remodelling

  2014cites this paper
• Multicenter Trials: Rationale and Examples †

  2014cites this paper
• Vascular balloon injury and intraluminal administration in rat carotid artery.

  2014cites this paper
• The bumpy road to evidence: why many research findings are lost in translation.

  2013cites this paper
• Influence of the Angiotensin Converting Enzyme Insertion or Deletion Genetic Variant and Coronary Restenosis Risk: Evidence Based on 11,193 Subjects

  2013cites this paper
• Innovations in studying in vivo cell behavior and pharmacology in complex tissues – microvascular endothelial cells in the spotlight

  2013cites this paper
• Genetic Polymorphism of Angiotensin Converting Enzyme and Risk of Coronary Restenosis after Percutaneous Transluminal Coronary Angioplasties: Evidence from 33 Cohort Studies

  2013cites this paper
• Arterial Wall Remodeling and Restenosis Following Vascular Reconstruction

  2013cites this paper
• Oxidative stress and pathological changes after coronary artery interventions.

  2013cites this paper
• Role of the renin-angiotensin system in the pathogenesis of intimal hyperplasia: therapeutic potential for prevention of vein graft failure?

  2012cites this paper
• Angiotensin Converting Enzyme Gene Insertion/Deletion Polymorphism and Cardiovascular Disease

  2012cites this paper
• Bradykinin-Mediated Cardiovascular Protective Actions of ACE Inhibitors

  2012cites this paper
• Angiotensin Antagonism in Coronary Artery Disease

  2012cites this paper
• The Clinical Potential of Endothelin Receptor Antagonists in Cardiovascular Medicine

  2012cites this paper
• ACE Inhibition, Endothelial Function and Coronary Artery Lesions

  2012cites this paper
• Pharmacological Approaches to the Prevention of Restenosis Following Angioplasty

  2012cites this paper
• Effect of Verapamil on Atherosclerosis

  2012cites this paper
• Relationship of genetic markers for atherosclerosis and long-term outcome after percutaneous coronary intervention with stenting.

  2012cites this paper
• Tissue-engineered vascular grafts for use in the treatment of congenital heart disease: from the bench to the clinic and back again.

  2012cites this paper
• Multiple mechanisms for the action of chymase inhibitors.

  2012cites this paper
• Targets of chymase inhibitors

  2011cites this paper
• Effect of a dihydropyridine-type calcium channel blocker on vascular remodeling after experimental balloon angioplasty.

  2011cites this paper
• Neointimal Hyperplasia Inhibition Effect of Angiotensin II Type 1 Receptor Blockers in Patients after Coronary Stent Implantation

  2011cites this paper
• Experimentally modified Fontan circulation in an adolescent pig model without the use of cardiopulmonary bypass

  2011cites this paper
• Lessons learned from advanced intracoronary imaging in patients with acute myocardial infarction.

  2011cites this paper
• Invasive Cardiac Procedures

  2011cites this paper
• Impact of the renin-angiotensin-aldosterone-system on cardiovascular and renal complications in diabetes mellitus.

  2010cites this paper
• New approaches to blockade of the renin-angiotensin-aldosterone system: chymase as an important target to prevent organ damage.

  2010cites this paper
• Angiotensin-converting enzyme inhibitor associated cough: deceptive information from the Physicians' Desk Reference.

  2010cites this paper
• Chymase as an important target for preventing complications of metabolic syndrome.

  2010cites this paper
• Prevention of Lesion Recurrence in Endovascular Devices

  2010cites this paper
• Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies

  2009cites this paper
• Impact of telmisartan on coronary stenting in patients with acute myocardial infarction compared with enalapril.

  2009cites this paper
• Quinaprilat-eluting stents do not attenuate intimal thickening following stenting in porcine coronary arteries.

  2009cites this paper
• Angiotensin II type 1 receptor blockade in the prevention of in-stent restenosis: systemic versus local delivery.

  2009cites this paper
• Synthesis and anti-platelet activity of novel arylsulfonate--acylhydrazone derivatives, designed as antithrombotic candidates.

  2008cites this paper
• Vascular protecting effect of angiotensin receptor blocker (ARB) on the radial artery graft.

  2008cites this paper
• Therapeutic and mechanistic explorations of in-stent restenosis in the rat aortic stenting model

  2008cites this paper
• Increased Expression of Angiotensin Converting Enzyme 2 in Conjunction with Reduction of Neointima by Angiotensin II Type 1 Receptor Blockade

  2008cites this paper
• Role of the Angiotensin II Type 2 Receptor in Arterial Remodeling after Wire Injury in Mice

  2008cites this paper
• Comparison of Selective AT1-Receptor Blockade Versus ACE Inhibition for Restenosis Prophylaxis in Patients With Peripheral Occlusive Arterial Disease After Stent Angioplasty: A Randomized, Controlled, Proof-of-Concept Study

  2007cites this paper
• ANGIOTENSIN II‐INDUCED GROWTH OF VASCULAR SMOOTH MUSCLE CELLS IS ASSOCIATED WITH MODULATION OF CELL SURFACE AREA AND PLATELET‐DERIVED GROWTH FACTOR RECEPTOR EXPRESSION

  2007cites this paper
• Management of hypertension in relation to acute coronary syndromes and revascularisation.

  2007cites this paper
• Odkrycie inhibitorów konwertazy angiotensyny - historia sukcesu

  2007cites this paper
• Univentricular Heart

  2007cites this paper
• Halofuginone inhibits neointimal formation of cultured rat aorta in a concentration-dependent fashion in vitro

  2007cites this paper
• ACE Inhibition in Heart Failure and Ischaemic Heart Disease

  2007cites this paper
• Chymase and Matrix Metalloproteinase

  2007cites this paper
• Missed opportunities for the secondary prevention of cardiovascular disease in Canada.

  2007cites this paper
• Angiotensin-Converting Enzyme and Vascular Remodeling

  2007cites this paper
• Pharmacogenomics of Renin Angiotensin System Inhibitors in Coronary Artery Disease

  2007cites this paper
• Chapter 61 – Hypertension in the Context of Acute Myocardial Infarction and Percutaneous Coronary Interventions

  2007cites this paper
• Epidemiology and Pathogenesis of Restenosis

  2007cites this paper
• Komprehensive Behandlungsstrategien zur Ergebnisoptimierung nach perkutaner koronarer Intervention

  2006cites this paper
• Pathological roles of angiotensin II produced by mast cell chymase and the effects of chymase inhibition in animal models.

  2006cites this paper
• Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials.

  2006cites this paper
• The Current Role of ACE-inhibitors for Secondary Prevention in Cardiovascular Disease; from Pathogenesis to Clinical Practice

  2006cites this paper
• Present status of outcome prediction of invasive coronary treatment by using genetic markers

  2006cites this paper
• Drug-eluting stents for infrainguinal occlusive disease: progress and challenges.

  2006cites this paper
• Tissue angiotensin II generating system by angiotensin-converting enzyme and chymase.

  2006cites this paper
• ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention).

  2006cites this paper
• ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention—summary article: A report of the American college of cardiology/American heart association task force on practice guidelines(ACC/AHA/SCAI writing committee to update the 2001 guidelines for percutaneous coronary intervention)

  2006cites this paper
• Application of a chymase inhibitor, NK3201, for prevention of vascular proliferation.

  2006cites this paper
• Upregulation of proteinase-activated receptors and hypercontractile responses precede development of arterial lesions after balloon injury.

  2006cites this paper
• Restenosis after percutaneous coronary intervention is associated with the angiotensin-II type-1 receptor 1166A/C polymorphism but not with polymorphisms of angiotensin-converting enzyme, angiotensin-II receptor, angiotensinogen or heme oxygenase-1

  2006cites this paper
• Effects of angiotensin-converting enzyme inhibitors or an angiotensin receptor blocker in combination with aspirin and cilostazol on in-stent restenosis.

  2006cites this paper
• ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention).

  2006cites this paper
• [Antiatherogenic effects of angiotensin converting enzyme inhibitors from positions (point of view) of evidence based medicine. Part I].

  2006cites this paper
• Towards a tailored approach in Percutaneous Coronary Interventions

  2006cites this paper
• Angiotensin antagonism in coronary artery disease: results after coronary revascularisation.

  2005cites this paper
• Pulmonary artery growth fails to match the increase in body surface area after the Fontan operation

  2005cites this paper
• Assessing the Likelihood of an Important Clinical Outcome: New Insights from a Comparison of Clinical and Actuarial Judgment

  2005cites this paper
• Inhibition of Intimal/Medial Hyperplasia by Perindopril in Canine Vein Grafts

  2005cites this paper
• The angiotensin II receptor blocker candesartan cilexetil reduces neointima proliferation after coronary stent implantation: a prospective randomized study under intravascular ultrasound guidance.

  2005cites this paper
• Expression, localisation and function of ACE and chymase in normal and atherosclerotic human coronary arteries.

  2005cites this paper
• Potential antithrombotic and fibrinolytic properties of the angiotensin converting enzyme inhibitors

  2005cites this paper
• Glyceryl trinitrate-induced angiotensin-converting enzyme (ACE) inhibition in healthy volunteers is dependent on ACE genotype.

  2005cites this paper
• Renin-Angiotensin System Intervention to Prevent In-Stent Restenosis: An Unclosed Chapter

  2005cites this paper
• Drug coated stents for carotid intervention.

  2005cites this paper
• Valsartan versus ACE inhibition after bare metal stent implantation--results of the VALVACE trial.

  2005cites this paper
• Indications for routine heart-catheterization after CABG and PTCA

  2005cites this paper
• Implications for Antiproliferative Therapy

  2005cites this paper
• Impact of frame selection on quantitative coronary angiographic analysis after coronary stenting

  2005cites this paper
• Percutaneous coronary interventions for coronary artery disease: the long and short of optimizing medical therapy

  2005cites this paper
• Clinical Trials: Viewpoint

  2004cites this paper
• Effects of altering infusion parameters on intimal hyperplasia following local catheter-based delivery into the rabbit iliac artery.

  2004cites this paper
• A single treatment with a specific chymase inhibitor, TY-51184, prevents vascular proliferation in canine grafted veins.

  2004cites this paper
• Angiotensin-Receptor Blockers: Revival of the Systemic Prevention of Restenosis?

  2004cites this paper
• Combined treatment with an AT1 receptor blocker and angiotensin converting enzyme inhibitor has an additive effect on inhibiting neointima formation via improvement of nitric oxide production and suppression of oxidative stress.

  2004cites this paper
• Chymase as a novel target for the prevention of vascular diseases.

  2004cites this paper